Introduction {#S1}
============

*Neisseria meningitidis* is a major obligate human pathogen that frequently colonizes the nasopharynx asymptomatically, in a state known as carriage ([@B1]). Occasionally, invasive meningococcal disease (IMD) occurs, through invasion of pharyngeal tissues, proliferation in blood (meningococcal septicemia), and crossing of the blood--brain barrier leading to meningitis ([@B2], [@B3]). More than 70,000 cases of IMD are reported annually worldwide with case fatality ratios between 5 and 15%, even with therapeutic intervention ([@B4], [@B5]). Debilitating neurological sequelae are common among survivors of IMD ([@B6]--[@B8]).

The use of currently available polysaccharide conjugate meningococcal vaccines has been effective against targeted serogroups (mainly serogroups A, C, W, and Y) within vaccinated populations ([@B9], [@B10]). For serogroup B strains, which account for more than 60% of IMD in the UK and Europe ([@B11], [@B12]), vaccine development has focused heavily on sub-capsular vaccine components owing to the unsuitability of the serogroup B capsule ([@B13]). One of these vaccines, 4CMenB (or Bexsero^®^), is a protein-based vaccine whose major components are the factor-H binding protein (fHbp) (variant 1.1), Neisserial heparin-binding antigen (NHBA variant 2), Neisserial adhesin A (NadA variant 3), and the detergent-extracted outer membrane vesicle component of the New Zealand epidemic strain (with PorA variant P1.4) ([@B14]). Like the polysaccharide conjugate vaccines, accruing data shows high effectiveness of 4CMenB ([@B15]). However, we are seeing a gradual recrudescence of carriage and disease to pre-vaccine levels through vaccine-driven strain replacement ([@B16]--[@B19]). In addition, there are concerns that the changing epidemiology of IMD ([@B20]--[@B22]) may lead to a significant reduction in the efficacy of the vaccines in the long term. These limitations, coupled with the huge potential of the meningococcus to generate extensive antigenic diversity (leading to vaccine/immune escape) ([@B23]) justify the search for novel vaccine candidate antigens.

Preclinical vaccine development methods are enriched by detailed analysis of the human immune response to etiological agents of infectious diseases. For example, with the development of high-throughput technologies, deep sequencing of the gene segments encoding the variable regions of antibody heavy (V~H~) and light (V~L~ = κ or λ) chains in a given B cell repertoire is providing valuable information useful in understanding adaptive immunity to infections, autoimmunity, and malignancies ([@B24], [@B25]). Identifying the targets of antibodies of interest by cloning and *in vitro* expression of V~H~ and V~L~ chains of B-cell antibodies is a powerful approach, which can be utilized to inform on the functional immunogenicity of both known and novel antigens. The use of this approach, termed reverse vaccinology 2.0 ([@B26]), in the cloning of neutralizing human recombinant monoclonal antibodies \[human monoclonal antibodies (hmAbs)\] from patients convalescing from viral infectious diseases is well documented; the first studies in the use of reverse vaccinology 2.0 focused on the isolation and functional characterization of antibodies targeting the dengue, HIV, and influenza viruses ([@B27]--[@B29]). The power of the approach lies in the expression of paired V~H~ and V~L~ regions from individual plasmablasts or memory B cells; the output being the expression of hmAbs mimicking natural V~H~ + V~L~ combinations induced in the host.

Because of the transience of peak plasmablast circulation \[reviewed in Ref. ([@B30])\] and the higher incidence of IMD among infants and toddlers (placing a limitation on blood sample volume), we aimed to assess whether reverse vaccinology 2.0 could be employed in the discovery of novel meningococcal antigens of vaccine potential. In this brief research report, we will outline findings relating to the following aims: (i) whether cross-reactive antimeningococcal hmAbs targeting surface proteins could be cloned from patient samples; and (ii) if these hmAbs possessed bactericidal activity against a wide panel of strains, specifically those not covered by the protein-based meningococcal vaccines.

Materials and Methods {#S2}
=====================

Ethics Statement and Study Participants {#S2-1}
---------------------------------------

Studies with human blood samples were approved by the London---Fulham Research Ethics Committee (Ref.: 11/LO/1982). Informed written consent was obtained from patients or their representatives in accordance with the Declaration of Helsinki. Patients were recruited following admission to the Imperial Healthcare (St. Mary's Hospital) Paediatric Intensive Care Unit (PICU), London, UK.

Patient SM-P02 was a 7-month-old baby who presented with fever, irritability, and reduced oral intake. Rapidly spreading petechial rash was detected a few hours after arrival at the hospital. Blood cultures confirmed meningococcal septicemia. Molecular typing of the isolate, M14-240312, revealed that it was a serogroup B strain (MenB). A 4 ml blood sample was collected 7 days post-admission to St. Mary's Hospital PICU, following confirmation of negative blood cultures.

Bacterial Strains {#S2-2}
-----------------

Assays performed with whole bacteria or cell lysates involved patient isolates M14-240312 and a 16-strain meningococcal panel reflecting the current genetic epidemiological prevalence in the UK (obtained from the UK Meningococcal Reference Unit, Public Health England, Manchester) (Table [1](#T1){ref-type="table"}). This 16-strain panel includes 10 strains genotypically mismatched for all the major 4CMenB antigens. Typing information was obtained from the *Neisseria* MLST database hosted on <https://pubmlst.org/neisseria/>. Meningococci were routinely grown on 5% horse blood agar or in brain heart infusion broth supplemented with 5% Levinthal's.

###### 

MenB strains composing the 17-strain screening panel.

  ----------------------------------------------------------------------------------------------------------------
  S/N   Isolate      PorA   FetA\   MLST                                  4CMenB antigen type                
                            VR                                                                               
  ----- ------------ ------ ------- ------------------------------------- --------------------- ------- ---- -----
  1     M14-240312   12-1   13-1    5-5                                   41/44                 2.19    2    --

  2     MC58         7      16-2    1-5                                   32                    1.1     3    110

  3     M07-240646   22     9       5-12                                  269                   2.19    17   --

  4     M07-240657   5-1    10-4    5-5                                   213                   3.294   18   --

  5     M07-240669   17-1   23      5-2                                   41/44                 2.19    31   --

  6     M07-240679   19     15      ND[^b^](#tfn2){ref-type="table-fn"}   269                   2.19    17   --

  7     M07-240680   22     14-6    ND                                    41/44                 2.19    43   --

  8     M07-240909   22     14      5-5                                   213                   2.19    18   --

  9     M08-240014   22     9       ND                                    269                   2.68    17   --

  10    M08-240107   22     9       ND                                    269                   3.59    17   --

  11    M08-240164   22     14      ND                                    213                   3.45    18   --

  12    M08-240276   22     14      5-5                                   213                   3.45    18   --

  13    M10-240474   19-1   15-11   3-9                                   269                   1.15    21   --

  14    M10-240476   22     14      5-5                                   213                   1.110   18   --

  15    M10-240480   7-2    4       1-5                                   41/44                 1.4     2    --

  16    M11-240016   7      16      3-3                                   32                    1.62    3    100

  17    M11-240123   5-1    2-2     5-8                                   11                    2.22    20   --
  ----------------------------------------------------------------------------------------------------------------

*^a^Dash (--) denotes absence of NadA in isolate*.

*^b^ND denotes no data, i.e. no typing information available for this antigen*.

Cell Sorting, cDNA Synthesis, and V~H~/V~L~ Cloning {#S2-3}
---------------------------------------------------

Peripheral blood mononuclear cells (PBMCs) were extracted from a 4 ml blood sample using a density gradient centrifugation method (Leucosep) and sorted singly into individual wells of 96-well plates containing catch buffer (10 mM Tris pH 8.0, 10 U RNAsin) as previously described ([@B31]). PBMCs were incubated with a cocktail of anti-human monoclonal antibodies targeting CD3 (PerCP/Cy5.5), CD14 (PerCP/Cy5.5), CD19 (RPE), CD20 (PerCP/Cy5.5), CD27 (FITC), CD38 (APC), and CD56 (PerCP/Cy5.5) for 30 min on ice, in the dark. Stained PBMCs were analyzed using a BD FACSAria III cell sorter. Plasmablasts were gated as follows: CD3^−^, CD14^−^, CD19^+^, CD20^−^, CD56^−^, CD27^high^, and CD38^high^. A single freeze-thaw cycle was used to lyse cells and release RNA. cDNA was synthesized from released RNA using the QIAGEN OneStep RT-PCR kit, as per manufacturer's protocols. A nested PCR was used to amplify the V~H~ and V~L~ regions; primers contained restriction endonuclease sites, which facilitated cloning into respective AbVec-IgH (*AgeI* + *SalI*), AbVec-Igκ (*AgeI* + *BsiWI*), or AbVec-Igλ (*AgeI* + *XhoI*) expression vectors.

Expression of hmAbs in Human Embryonic Kidney (HEK-293) Cells {#S2-4}
-------------------------------------------------------------

HEK-293 cells were transiently transfected with cognate plasmid pairs using polyethyleneimine as transfection agent, as previously described ([@B31]). Culture supernatants were harvested after 72 h. HmAbs were purified from culture supernatants with single-use Protein G spin columns (Ab SpinTrap, GE Healthcare), as per manufacturer's instructions.

Assessment of hmAb Specificity {#S2-5}
------------------------------

HmAb reactivity to surface-bound meningococcal antigens was assessed using indirect cell-based ELISAs, as previously described ([@B32]). Briefly, inactivated bacterial whole cell suspensions were normalized to an OD600 of \~0.5. Whole cells (100 µl of cell suspensions) or 1 µg of 4CMenB in Carbonate-Bicarbonate buffer (Sigma-Aldrich, cat. no. C3041) were transferred into designated wells of flat-bottom polystyrene 96-well plates and incubated at 4°C overnight. Wells were subsequently incubated with 200 µl of blocking buffer (PBS, 0.05% Tween-20, 1% BSA) for 1 h at room temperature prior to addition of 100 µl of an appropriate dilution of hmAbs or plasma IgG. Following a 1-h incubation, wells were washed thrice to remove unbound antibodies. A 1:2,000 dilution of an anti-IgG alkaline phosphatase conjugate (Sigma-Aldrich, cat. no. A9544) was used to probe wells for 1 h at room temperature. Wells were washed five times before addition of a phosphatase substrate (Bio-Rad, cat. no. 172-1063) as per the manufacturer's instructions. Signal detection was performed at OD405 using a microplate reader.

Further investigations into hmAb reactivity were performed using western blotting, as described elsewhere ([@B33]).

Serum Bactericidal Activity (SBA) Assay {#S2-6}
---------------------------------------

Functional activity of antimeningococcal IgG was determined using the standardized SBA assay ([@B34]). Briefly, 10^3^ CFU meningococci were incubated with IgG (hmAb or purified total plasma IgG) (final assay concentration of 25%) and exogenous human complement (25%) for 90 min in a humidified CO~2~ incubator at 37°C, with gentle shaking. IgG that effected a reduction in meningococcal CFU by \>50% after 90 min compared to negative controls (complement only; IgG only) was considered to possess SBA activity.

Results {#S3}
=======

Induction of a Functional Immune Response in Patient SM-P02 {#S3-1}
-----------------------------------------------------------

Flow cytometric analysis showed that the circulating plasmablast population in patient blood was low, measured at 0.3% (Figure [1](#F1){ref-type="fig"}). To assess whether these plasmablasts represented a functional response to the meningococcal infection, total IgG purified from patient plasma was assayed for bactericidal activity. Purified total IgG, rather than plasma, was assayed because of the presence of administered antibiotics in patient plasma. Reactivity of purified SM-P02 IgG to the patient isolate (M14-240312) and two other strains (MC58, which expresses the fHbp variant 1.1 in 4CMenB; and M08-240276, which is mismatched for all 4CMenB antigens) was assessed in ELISAs prior to assessment of SBA activity against the three strains. SM-P02 IgG bound to the infecting isolate, M14-240312, in cell-based ELISAs with corresponding SBA activity against the isolate. Despite significant binding of SM-P02 IgG to MenB strains MC58 and M08-240276 in ELISAs, no bactericidal activity was discerned against these strains. Thus, the induction of a specific bactericidal response in the patient to M14-240312 was confirmed (Figure [2](#F2){ref-type="fig"}A). Furthermore, the antimeningococcal immune response in patient SM-P02 was exclusive of the antigenic components of 4CMenB as no reactivity of SM-P02 plasma IgG to the vaccine antigens was discerned in ELISAs, under the experimental conditions employed in this study (Figure [2](#F2){ref-type="fig"}B).

![Quantitative analysis of patient SM-P02's adaptive immune response to a MenB infection. Flow cytometry plots were gated for plasmablasts by CD3^−^, CD19^+^, then CD27^+/high^ and CD^38+/high^.](fimmu-09-01621-g001){#F1}

![Qualitative analyses of patient SM-P02's adaptive immune response to a MenB infection. **(A)** Serum bactericidal response of SM-P02 plasma IgG (final assay concentration of 192 µg/ml) to the infecting MenB strain, M14-240312. **(B)** Reactivity of SM-P02 plasma IgG to MenB strains and 4CMenB in ELISA. Cells normalized to OD600 of \~0.5 or 1 µg of 4CMenB were used as antigen in ELISAs (duplicate wells). Error bars represent SEM. Data were obtained from three biological assay replicates (*n* = 6).](fimmu-09-01621-g002){#F2}

*In Vitro* Cloning and Expression of Antimeningococcal Antibodies From Patient Plasmablasts {#S3-2}
-------------------------------------------------------------------------------------------

Amplification of the V~H~ and V~L~ (κ or λ) gene segments from 336 plasmablasts occurred at a PCR efficiency of 80%. Sequencing of these variable region gene segments showed biased usage of the IGHV3-7:IGλV2-8 gene pair, accounting for 16.7% of V gene usage. Of 139 recombinant hmAbs that were successfully expressed in HEK-293 cells, eight (Figure [3](#F3){ref-type="fig"}A) were reactive with the infecting MenB strain (M14-240312) and, in varying degrees, with the other members of the MenB strain panel (Figure [3](#F3){ref-type="fig"}B). None of these eight hmAbs were reactive with *Actinobacillus pleuropneumoniae* cells (a porcine respiratory pathogen). All antimeningococcal hmAbs possessed the IGHV3 class gene, albeit with different subclasses and light chain gene pairs; the exception being P02-4F2 (IGHV4-59:IGκV1/1D-39). Two of these hmAbs (P02-5E10 and P02-6E9), however, possessed identical V gene pairs (IGHV3-30:IGκV4-1).

![Characterization of patient-derived human monoclonal antibodies (hmAbs). **(A)** SDS-PAGE analysis of \~2 μg of purified hmAbs. **(B)** Reactivity of hmAbs was performed using formalin-fixed bacterial cells normalized to an OD600 of \~0.5. A 1:1,000 dilution of each hmAb was employed. A representative dataset from three biological replicates is presented. The coating antigens (protein antigens or cells) are represented by numbers on the *x*-axis as follows: 1. 4CMenB; 2. M14-240312; 3. MC58; 4. M07-240646; 5. M07-240657; 6. M07-240669; 7. M07-240679; 8. M07-240680; 9. M07-240909; 10. M08-240014; 11. M08-240107; 12. M08-240164; 13. M08-240276; 14. M10-240474; 15. M10-240476; 16. M10-240480; 17. M11-240016; 18. M11-240123; 19. *A. pleuropneumoniae*.](fimmu-09-01621-g003){#F3}

Specificity of the antimeningococcal hmAbs for the serogroup B capsule was ruled-out using the periodate assay, described in Ref. ([@B35]) (data not shown). Denaturing western blot data showed highly specific reactivity of three hmAbs (P02-1A1, P02-5E10, and P02-6E9) with a \~35 kDa meningococcal protein present in six members of the 17-strain panel (\~35%). The target epitope of hmAb P02-1A1 was present in more strains (*n* = 6) than those of hmAbs P02-5E10 (*n* = 3) and P02-6E9 (*n* = 2) (Figure [4](#F4){ref-type="fig"}). The other five hmAbs, which were broadly cross-reactive with the strain panel (collectively recognizing 12 out of 17 strains), were non-reactive in denaturing western blots.

![Specificity of patient-derived antimeningococcal (hmAbs) for linear epitopes in denaturing western blots. Lysates from normalized suspensions of selected MenB strains were used as template in western blot experiments. A 1:1,000 dilution of each hmAb was employed.](fimmu-09-01621-g004){#F4}

Cloned Antimeningococcal hmAbs Possess SBA Activity Against Patient Isolate M14-240312 {#S3-3}
--------------------------------------------------------------------------------------

To assess the functional activity of cloned recombinant hmAbs, SBAs were performed using purified hmAbs at a final assay concentration of 80 µg/ml. Three hmAbs (P02-1A1, P02-5E10, and P02-6E9), in synergy with exogenous human complement, possessed SBA activity against strain M14-240312. All other hmAbs were non-bactericidal (Figure [5](#F5){ref-type="fig"}).

![SBA of patient-derived antimeningococcal human monoclonal antibodies (hmAbs) versus patient isolate, M14-240312. Assays were performed with hmAbs normalized to final assay concentration of 80 µg/ml, in three biological replicates. Percentage survival after 60-min incubation (T60) in the presence of 25% human complement versus inoculum (T0) is shown.](fimmu-09-01621-g005){#F5}

SBA Activity of hmAbs Is Strongly Linked to Surface Expression of Target Epitopes {#S3-4}
---------------------------------------------------------------------------------

To assess the breadth of SBA exhibited by hmAbs P02-1A1, P02-5E10, and P02-6E9, each hmAb was assayed for bactericidal activity against the 17-strain panel. HmAb P02-1A1-mediated killing of the patient isolate, M14-240312, and four other strains to which it bound in immunoassays (M07-240646, M07-240657, M08-240014, and M10-240474). Only one strain, M07-240669, which showed positive reactivity with hmAb P02-1A1 in immunoassays was resistant to SBA activity of P02-1A1.

Consistent with results obtained with P02-1A1, hmAb P02-5E10 possessed SBA activity against strain M10-240474 (to which it bound in immunoassays) but not strain M07-240669, suggesting resistance of M07-240669 to complement-dependent killing. Interestingly, all three bactericidal hmAbs could mediate killing of other strains to which no discernible reactivity was found in immunoassays; hmAb P02-1A1 reproducibly mediated killing of strain M08-240276 while both P02-5E10 and P02-6E9 mediated killing of strain M10-240474 (Figure [6](#F6){ref-type="fig"}; Table [2](#T2){ref-type="table"}).

![SBA of P02-1A1, P02-5E10, and P02-6E9 versus MenB strains. Numbers represent strains as follows: 1. M14-240312; 2. MC58; 3. M07-0240646; 4. M07-0240657; 5. M07-0240669; 6. M07-0240679; 7. M07-0240680; 8. M07-0240909; 9. M08-0240014; 10. M08-0240107; 11. M08-0240164; 12. M08-0240276; 13. M10-240474; 14. M10-240476; 15. M10-240480; 16. M11-240016; 17. M11-240123. Assays were performed with hmAbs normalized to a final assay concentration of 80 µg/ml, in three biological replicates.](fimmu-09-01621-g006){#F6}

###### 

Summary table showing reactivity of the bactericidal human monoclonal antibodies---P02-1A1, P02-5E10, and P02-6E9---in immunoassays (ELISA and western blot), and SBA activity versus the 17-strain MenB panel.

  S/N   Isolate      P02-1A1   P02-5E10   P02-6E9             
  ----- ------------ --------- ---------- --------- ---- ---- ----
  1     M14-240312   \+        \+         \+        \+   \+   \+
  2     MC58         --        --         --        --   \+   --
  3     M07-240646   \+        \+         --        --   --   --
  4     M07-240657   \+        \+         \+        \+   --   --
  5     M07-240669   \+        --         \+        --   \+   --
  6     M07-240679   --        --         --        --   --   --
  7     M07-240680   --        --         --        --   --   --
  8     M07-240909   --        --         --        --   --   --
  9     M08-240014   \+        \+         --        --   --   --
  10    M08-240107   --        --         --        --   --   --
  11    M08-240164   --        --         --        --   --   --
  12    M08-240276   --        \+         --        --   --   --
  13    M10-240474   \+        \+         --        \+   --   \+
  14    M10-240476   --        --         --        --   --   --
  15    M10-240480   --        --         --        --   --   --
  16    M11-240016   --        --         --        --   --   --
  17    M11-240123   --        --         --        --   --   --

*I, immunoassay (ELISA and/or western blotting); SBA, serum bactericidal assay*.

*Plus (+) denotes positive reactivity in immunoassays or bactericidal activity in SBA*.

*Dash (--) denotes no discernible reactivity in immunoassays or bactericidal activity in SBA*.

Discussion {#S4}
==========

Despite vaccination, the ongoing threat from IMD is unquestionable, especially in the African meningitis belt, justifying the search for novel approaches to vaccine candidate discovery. Reverse vaccinology 2.0 has been useful in understanding the human adaptive immune response to disseminated viral ([@B36], [@B37]) and bacterial infections ([@B38], [@B39]). Hence, it presents as a potentially powerful tool that may identify novel meningococcal vaccine candidate antigens or reinforce the candidacy of some known antigens.

In the present study, we succeeded in isolating functional hmAbs from a 7-month-old patient convalescing from IMD despite challenging practical issues. The most affected age group for IMD is 6- to 24-months, and patients presenting at the St. Mary's PICU were mostly in this age group---children from whom the availability of sufficient quantities of blood sample for the isolation of PBMCs was very limited (4 ml). The isolation of specific antimeningococcal plasmablasts was further complicated by a paucity of knowledge on the magnitude and timing of peak plasmablast responses following primary meningococcal infection in infants. The plasmablast population measured in the single sample obtained at 7 days post-admission analyzed in this study was 0.5%. Plasmablast population following acute infection with dengue virus ([@B37]) occurred at 6--7 days postinfection. While the induction of peak plasmablast response following infection with nosocomially acquired bacteria such as *Acinetobacter baumanii* occurred in most patients at 8--16 days with 40--80% of the total B-cell population being plasmablasts, they composed \>2% of B-cell population in patient samples obtained at 0--7 days postinfection ([@B38]). The low plasmablast induction seen in IMD patient SM-P02 may, therefore, be patient-specific and the timing of the peak level of cycling plasmablasts was likely missed (less than or more than 7 days post-admission). It is also plausible that low plasmablast induction is characteristic of a population at particular risk of IMD. Larger patient cohorts will be required to investigate this theory. Optimization of the IgG-cloning technique to increase the number of antimeningococcal plasmablasts using a recently published Ig capture-based assay ([@B40]) should improve productivity of the approach.

Reactivity of the antimeningococcal hmAbs isolated in this study with heterologous MenB strains possessing disparate PorA types strongly suggests that the antigen target of the hmAbs is not PorA, the immunodominant meningococcal antigen. It is likely that the three bactericidal hmAbs are reactive with a similar linear epitope contained in a yet-to-be identified ca. 35 kDa antigen. This 35 kDa antigen is surface-expressed in \~35% of the MenB strains, with heterologous 4CMenB antigen types, employed in this study. It is pertinent to note, however, that the \~35% presence of the linear epitope is specific to hmAbs generated in this study, and the antigen which it composes may possess more immunogenic surface-exposed epitopes and exhibit a wider presence among MenB and other meningococcal strains. One of these bactericidal hmAbs, P02-1A1, is reactive with a more diverse strain panel and possesses a higher bactericidal titer than hmAbs P02-5E10 and P02-6E9. This could be a result of somatic hypermutation of the P02-5E10 and P02-6E9 antibodies leading to the production of hmAb P02-1A1 with enhanced binding efficiency (affinity and/or avidity). Determination of the unequivocal identities of these hmAbs and their reactivities/SBA with other serogroups is currently ongoing. Taken together, data generated so far on these bactericidal hmAbs (P02-1A1, P02-5E10, and P02-6E9) strongly suggest that their target is not PorA, fHbp, or any of the 4CMenB recombinant antigens signifying its novelty and most importantly, candidacy for inclusion in future vaccine preparations. It is acknowledged, however, that while our current data suggest that the 35 kDa antigen is absent from the NZ OMV component of 4CMenB, further work is required to determine its unequivocal absence. Given the need for protein antigens that would compose improved or entirely novel cross-serogroup antimeningococcal vaccines, data from this study show that reverse vaccinology 2.0 can be employed as a useful tool in identifying functionally immunogenic antimeningococcal antigens.
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